The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination-Reference-Cited by-同舟云学术

The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination

Published:2023-01 Issue: Volume:69 Page:104425
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Baker David^ORCID,Forte Eugenia,Pryce Gareth,Kang Angray S.,James Louisa K.,Giovannoni Gavin,Schmierer Klaus

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference187 articles.

1. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial;Abhishek;Lancet Respir. Med.,2022

2. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther. Adv. Neurol. Disord.,2021

3. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod;Achiron;J. Neurol.,2022

4. SARS-CoV-2 mRNA vaccination in people with multiple sclerosis treated with fingolimod: protective humoral immune responses may develop after the preferred third shot;Achtnichts;Vaccines (Basel),2022

5. Different type and timing of S1P receptor modulator therapy impacts T and B cell response after SARS-CoV2 vaccination P316;Akgün;Multip. Scler. J.,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies;Neurologic Clinics;2024-02

2. POST-COVID-19 LUNG PATHOGENESIS AND PATHOMORPHOLOGY;Ulyanovsk Medico-biological Journal;2023-12-27

3. Exploring adverse events associated with sphingosine-1-phosphate modulators: a pharmacovigilance study using the FDA Adverse Event Reporting System Database;2023-09-09

4. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC);Vaccines;2023-08-16

5. SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis;Annals of Clinical and Translational Neurology;2023-08-07